7,678 8,300
Loss from continuing operations before
interest (7,220) (7,839)
Interest income, net 117 604
Loss from continuing operations (7,103) (7,235)
Loss from discontinued operations (652) (1,153)
Net loss $ (7,755) $ (8,388)
Basic and diluted loss per share:
Loss per share from continuing
operations $ (0.12) $ (0.12)
Loss per share from discontinued
operations (0.01) (0.02)
Net loss per share (0.13) (0.14)
Basic and diluted weighted average number
of common shares outstanding 61,280,155 61,221,075
SELECTED BALANCE SHEET DATA
(in thousands)
As of March 31,
2008 As of December 31,
(unaudited) 2007
Cash and cash equivalents $ 14,702 $ 4,350
Short-term investments 26,191 42,139
Total current assets 43,036 49,016
Working capital 34,711 42,810
Total assets 86,221 91,291
Long term debt 21,711 21,629
Stockholders' equity 55,795 63,065
'/>"/>SOURCE Novavax, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
Novavax CEO to Present at BIO CEO & Investor Conference2.
Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC3.
Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)4.
Novavax CEO to Present at the World Vaccine Congress 20085.
Novavax Opens Its First U.S. Vaccine Plant6.
Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call7.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound8.
QMed, Inc. Reports July Medicare SNP Enrollments9.
Phlo Affiliate Reports Expanded Coverage to Oregon Border10.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results11.
Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007